Skip to content

Study · Not a test of the peptide alone · 2001

1 result

[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].

Kurysheva NI, Shpak AA, Ioĭleva EE, Galanter LI, Nagornova ND, Shubina NIu, Shlyshalova NN

Vestnik oftalmologii1 Jul 2001Cited by 2 (Europe PMC)

PMID11569188 (opens in a new tab)PepBankPUB-11569188

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semax.

  1. 01HumanNot a test of Semax aloneObservational studyEfficacy outcome

    In glaucoma patients with normalized ophthalmic tone, a neuroprotective therapy complex that included semax showed advantages over traditional neuroprotective treatment in electrophysiological and computer examinations.

    In plain wordsIn glaucoma patients, a treatment package that included semax looked better than usual nerve-protection treatment on eye tests. The package has several parts.

    Peptide
    Semax
    Outcome
    Direction not reportedElectrophysiological and computer-assessed outcomes in glaucomatous optic neuropathy
    Study

    n: not reported in source

    Comparator
    Traditional neuroprotective treatment
    Outcome group
    Neuroprotection · Eye

    Source sentences

    Summary
    Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma.
    1 context sentence
    Summary · context
    A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone.

    In this study, Semax was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semax.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.